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iscussion
r J. Brown (Indianapolis, Ind). We at Indianapolis completely
gree with your comments that you should try to reconstruct the
ulmonary valve every time you have to cross the annulus. We
ave used the polytetrafluoroethylene (Gore-Tex; WL Gore and
ssociates, Flagstaff, Ariz) monocusp.
The illustrations in your presentation look similar to the illus-
rations of the monocusp with the exception that you sew the edge
f your pericardial patch augmentation to the residual cut edges of
he leaflet that you cut across. And when your annulus is only 6
m, and I look at those valves, they’re so dysplastic, sewing a
ericardial patch to the edges of the leaflets just seems kind of
ifficult in a 3-, 4-, or 5-month-old child. So I wonder, the patches
hat you actually sew into these patients must be much wider than
he rest of the cusps put together to get an annulus diameter big
nough for that child.
When we originally started using polytetrafluoroethylene
Gore-Tex) monocusps, we sewed them to the pulmonary artery
all rather than the residual leaflet tissue. They were big enough
o be draped across the back of the RVOT so that it made it a
onocusp. How do your patch dimensions compare with our
olytetrafluoroethylene (Gore-Tex) monocusps? We know that our
olytetrafluoroethylene (Gore-Tex) monocusps last 2 or 3 years,
nd I am interested to find out whether these pericardial cusp s
46 The Journal of Thoracic and Cardiovascular Surgery ● Marcugmentations will last even a longer period of time. So that’s the
rst question. Is there really a difference between your technique
nd what we’ve been doing for 10 or 12 years?
Dr Anagnostopoulos. I think the difference is that by suturing
he pericardial tissue into the native valve apparatus, we try to use
he hinge mechanism of the valve and make it coapt with the rest
f the tissue. That cannot be done in the subset of patients in whom
he annulus is less than 4 or 5 mm, and in very dysplastic valves.
n these patients, the transannular patch is still our technique of
hoice.
To answer your question, I think, yes, our cusp is bigger than
he monocusp, the way I understand it by looking at your illustra-
ions. The monocusp is a technique that we don’t use at UCSF. The
ericardium is more pliable and gives you more lead to be able to
se a wider patch than the traditional monocusp.
Dr Brown. My second question is that at least in people who
ave used a biologic monocusp, a cusp from a homograft, autol-
gous pericardium, or bovine pericardium, none of them have
emained functional after about 3 or 4 months. Your follow-up is
.5 months, on average, with a follow-up of more than 2 years. Do
ou think your monocusps for some reason are going to be more
urable than those of everybody else who has tried the biologic
onocusp?
Dr Anagnostopoulos. The only reason why this could happen,
f it does (and as you said, we don’t have the data yet), is because
t is attached to the valve tissue itself. The theoretic potential of
rowth of the remaining native valve tissue exists. I think only
ime will tell.
Dr Brown. About 25 patients, or 27% of your patients, who
ad the cusp augmentation had moderate to severe PI. What do
hose cusps that failed look like? Are they fixed in the open
osition, as I would expect? Are they still mobile and they just
eren’t sized right? Why do 25% of your patients have moderate
o severe PI early after operation?
Dr Anagnostopoulos. They are fixed in the open position as
ou described. This probably represents technical problems with
he construction of this pericardial cusp augmentation flap. It
ostly happened in the beginning of our experience. Dr Sung, in
is article, quotes a similar problem in 2 of his 18 patients. The rate
f deterioration in his study was 17% in 2 years and was 17% in
urs as well. So I think that it had to do with the way we did it, and
think we learned better how to do that as time went by. I don’t
emember, in the last part of our experience, seeing that problem
nymore. That was part of our learning curve with the technique.
Dr Brown. I congratulate you and your group for attempting to
econstruct the pulmonary valve in every transannular patch re-
onstructive. We totally agree. I think time will only tell whether
his biologic cusp augmentation is going to have the same fate that
thers have or whether it will be better.
Dr Y. Kawashima (Minoo City, Japan). I congratulate Dr
nagnostopoulos and his coauthors for their excellent results of
ransatrial–transpulmonary repair for patients with TOF, particu-
arly in patients who underwent pulmonary valve augmentation.
s you may know, I started this transatrial–transpulmonary repair
or TOF in 1978, and I have simultaneously repaired the stenotic
ulmonary valve precisely using the cusp augmentation technique
ith an autologous pericardium when necessary with a methodimilar to that reported today.
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DRecently I reviewed the late result of the initial 110 patients
ho underwent operation 16 to 28 years ago at the age of 5 years
r less. There was 1 operative death, and 1 patient died 18 years
fter surgery. Among the other 108 patients, followed on an
verage of 22 years, 8 patients underwent reoperation, 7 for
ecurrent infundibular stenosis and 1 for calcified annular patch;
owever, no patient underwent reoperation for pulmonary regur-
itation.
I presume this is because of the somewhat functioning repaired
alve and a slightly enlarged pulmonary annulus. Excessive en-
argement of the pulmonary annulus was not necessary in our
eries because of the initially functioning pulmonary valve.
I agree with the author’s conclusion that pulmonary valve
epair using the cusp augmentation technique reduces the inci-
ence of postoperative pulmonary regurgitation, and my conclu-
ion is that precisely performed cusp augmentation reduces pul-
onary regurgitation even on an average of 22 years after surgery.
Dr Anagnostopoulos. Thank you for those comments.
Dr M. Wojtalik (Poznan, Poland). According to the drawing
ou have presented, it seems that there are 2 large patches recon-
tructing the RVOT, 1 inside creating the cusp and 1 outside. I
ould be afraid about the creation of the clotting between and
bstructing the RVOT. Did you observe such a complication?
Dr Anagnostopoulos. We followed those patients, and at this
edian follow-up of 8 months we haven’t seen any clots. One
atient had to undergo reoperation for residual RVOT obstruction,
ut during the operation it was clear that this was because of the
bstructing muscle fibers in the outflow and not because of the
usp obstructing the valve at the valvar level.
Dr S. Bradley (Charleston, SC). What do you and Dr Karl
hink are the best anatomic selection criteria for using this tech-
ique? It sounds like it would be difficult to use with a very small
ulmonary valve (a z score of 4 or so) or a stenotic unicusp
alve, as opposed to a valve that was mildly stenotic (z scores of
2 to 3). Is that fair, and do you have those criteria?
Dr Anagnostopoulos. Yes, that’s fair. The ideal valve for this
echnique is one that has the commissures at the 3 and 9 o’clock
ositions so the anterior leaflet can be bisected in the midline.
hose are anything from 50% to 70% of the valves, according to
r Kawashima’s study from 1981, and according to Steward and i
The Journal of Thoracicolleagues’ series from last year that was presented at the Society
f Thoracic Surgeons meeting. So I think it can be done. When the
ommissures are aligned at the 6 and 12 o’clock positions and you
ut through the anterior commissure, there is not a lot of valve to
ew and you end up reconstructing the RVOT with what looks
ore than a monocusp valve. But when you have valves that are
riented at the 3 and 9 o’clock positions, then you can really do it
ecause there is a nice remnant to sew your valve augmentation
ap on.
Dr A. Schlichter (Buenos Aires, Argentina). I have a short
omment and 1 question:
First, it takes a little longer to apply 2 patches than only 1. What
e do is prepare our patch with untreated pericardium, adapted to
he exact size that the patient needs to have the pulmonary artery
nd annulus enlarged, according to tables and body surface area.
aving measured the patient’s annulus, a resident produces the
onocusp on the patch, and we then suture the patch on the
nnulus.
Are you taking into consideration the diameter that you need to
btain for the enlarged pulmonary annulus and artery? I am asking
his because we are now concerned about long-standing pulmonary
alve incompetence, which is in relation to the diameter of the
ulmonary artery at the time of its surgical enlargement. If we enlarge
t too much, we are probably going to have more PI in the long term
nd more reoperations for TOF. It has been some time since we
hanged our policy of wide enlargements, and we now prefer to
ailor patches to the patient’s needs or even a little smaller. In the
ong term we think it is better to have a nonsignificant pressure
radient than severe pulmonary valve incompetence.
Dr Anagnostopoulos. When we construct that patch, we have
n mind what the pulmonary valve annulus should be for that
articular patient. To not prolong the operation, you cannot really
ave it preformed and suture it on because you have to be able to
ee the valve. Otherwise you can end up creating technical prob-
ems; you can tear those valves that sometimes are dysplastic and
ery thinned out.
To do that, we snare the patent foramen ovale, and then we do
his part of the reconstruction on the beating heart. So even though
t may take some more time, at least that’s not ischemia time.
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